Medtronic touts Micra leadless pacer post-approval registry study data

Medtronic (NYSE:MDT) today released one-year results from the post-approval registry study of its Micra leadless transcatheter pacing system, touting a high implant success rate and a low complication rate. Results from the study are slated to be presented tomorrow at the Heart Rhythm Society’s annual scientific sessions conference in Boston, the Fridley, Minn.-based company said. Medtronic’s Micra pacemaker is approximately 1/10th the size of a conventional pacemaker, and is designed to be implanted via catheter into the right ventricle to deliver single-chamber pacing. The system features a battery with an estimated 12-year battery lifespan, and is cleared for use with full-body MRI scans. The FDA approved Micra in April 2016. The post-approval registry study examined data from 1,817 patients across 23 countries compared to a reference dataset of 2,667 patients with transvenous pacemakers. “Medtronic is committed to providing the most advanced technologies that improve lives of patients around the world. The leadless Micra pacemaker is an excellent example of one of those technologies, and now we know that it performs well for patients in a real world setting as well as in a clinical trial,” Medtronic cardiac rhythm and heart failure division chief medical officer Dr. Rob Kowal said in a press release. New data from the registry study indicated that the Micra system had an implant success rate of 99.1% with a major complication rate of 2.7% throug...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials Medtronic Source Type: news